The transmembrane mucin, MUC4, is aberrantly expressed with a high incidence in human pancreatic adenocarcinomas and plays an important role in the pathogenesis of the disease. Our recent studies have shown that interferon-c (IFNc) and retinoic acid (RA) are important regulators of MUC4 in pancreatic tumour cells. Induction of MUC4 by IFNc occurs via a novel pathway involving upregulation of the signal transducer and activator of transcription 1 (STAT-1), whereas its stimulation by RA requires mediation by the transforming growth factor b-2 (TGFb-2). In this study, we have investigated the molecular mechanisms underlying the interaction of IFNc and RA in MUC4 regulation in pancreatic tumour cells. We demonstrate that these reagents exert a synergistic induction of MUC4. Interestingly, while the upregulation of STAT-1 by IFNc is partially inhibited by RA, IFNc is shown to repress RA-driven TGFb-2 induction, pointing to the involvement of alternative mechanism(s) in IFNc-RA synergism. Moreover, a dose-dependent and cooperative induction of MUC4 promoter activity suggests a regulation at the transcriptional level, most likely by STAT-1 and RAR/RXR (RA receptor/retinoic X receptor) or other IFNc/RAinduced secondary intermediate effectors. Our findings provide potential mechanisms that may account for the aberrant expression of MUC4 in pancreatic tumour cells and expose a novel molecular mechanism of gene induction, whereby a reprogramming of signalling pathway through alternative route(s) operates during a synergistic interaction of biological modifiers.
Introduction
Pancreatic cancer is a highly lethal malignancy characterized by an extremely poor prognosis (Warshaw and Fernandez-del Castillo, 1992; Reber, 1998; Jemal et al., 2003) . Efforts made to improve the treatment of this neoplastic disorder have been hampered, in large part, by the elusive nature of its initiation and progression. Nonetheless, a wide variety of biochemical and/or genetic aberrations commonly associated with pancreatic cancer have been identified, owing to the advent of newer and more efficient molecular biological and genetic techniques (Reber, 1998; Sirivatanauksorn et al., 1998) . Among the series of genes whose expression profiles are frequently altered in pancreatic cancer are mucins (MUC), the members of an expanding class of high-molecular-weight glycoproteins (Gendler and Spicer, 1995; Moniaux et al., 2001; Hollingsworth and Swanson, 2004) . MUC4, a large transmembrane mucin, is aberrantly expressed in the majority (70-80%) of pancreatic tumours and tumour cell lines while remaining undetectable in the normal pancreas (Andrianifahanana et al., 2001) . In recent years, there has been increasing evidence supporting the role of this tumourassociated mucin in the pathogenesis of pancreatic cancer (Andrianifahanana et al., 2001; Swartz et al., 2002; Singh et al., 2004) . Comparative expression analyses have revealed a positive correlation between MUC4 levels, the differentiation status of pancreatic tumour cell lines (Andrianifahanana et al., 2001) , and tumour grading in accordance with a model of pancreatic tumour progression (Swartz et al., 2002) . Moreover, functional studies using antisense-and/or short-interfering RNA (siRNA) oligonucleotide-based knockdown or ectopic expression of MUC4 have provided substantial evidence of its role in the promotion of pancreatic tumour cell growth and metastasis in vivo (Singh et al., 2004) . Taken together, these observations suggest an intimate link between aberrant MUC4 expression and the pathogenesis of pancreatic cancer. Therefore, an improved understanding of mechanism(s) underlying the regulation of this mucin gene may help to identify key biochemical events and biologically relevant factors that may account for its aberrant upregulation in pancreatic tumour cells in vivo. This, in turn, may significantly facilitate the design of therapeutic strategies using MUC4 as a novel molecular target.
In our recent studies, we have used a pancreatic tumour cell system to investigate the mechanisms regulating MUC4 expression. This model system is comprised of the MUC4-producing parental cell line, CD18/HPAF, and its serum-free (SF)-adapted derivative, CD18/HPAF-SF, which expresses low or undetectable endogenous MUC4 (Choudhury et al., 2000) . We have demonstrated that interferon-g (IFNg) and retinoic acid (RA) (Choudhury et al., 2000) can potently induce MUC4 expression in CD18/HPAF-SF cells. From a mechanistic standpoint, the proinflammatory cytokine, IFNg, canonically activates the Janus kinase (JAK)/signal transducer and activator of transcription 1 (STAT-1) pathway via binding to its cell-surface receptor complex (IFNg receptor (IFNGR) subunits 1 and 2). Activation of receptor-associated JAKs (JAK-1 and JAK-2) subsequently ensues, leading to a cascade of molecular events that culminate in the phosphorylation of latent cytoplasmic STAT-1 protein at residues Tyr 701 and Ser
727
. Activated STAT-1 molecules homodimerize and translocate to the nucleus to induce the transcription of target genes (Bach et al., 1997; Park and Schindler, 1998; Ramana et al., 2002) . Stimulation of MUC4 expression by IFNg in CD18/HPAF-SF cells was shown to engage a pathway, whereby upregulation of constitutively Ser 727 -phosphorylated STAT-1 promoted the nuclear accumulation of this transcription factor and represented a key regulatory step in MUC4 induction . In contrast, the classical STAT-1 Tyr 701 phosphorylation (Bach et al., 1997; Park and Schindler, 1998; Ramana et al., 2002) did not appear to play an essential role in MUC4 induction . RA, on the other hand, is a differentiation factor commonly encountered in the blood plasma (Hara et al., 2001) that exerts its effect via the nuclear RA receptors (RAR (isoforms a, b, and g)) and retinoic X receptors (RXR (isoforms a, b, and g)). Typically, heterodimers of RAR/RXR act as transcription factors to promote the transcription of RA-induced genes (Leid et al., 1992; Hu et al., 2002) . In CD18/HPAF-SF cells, MUC4 induction by RA was a two-step process that involved the transforming growth factor b-2 (TGFb-2) as a key mediator. RA treatment elicited RARa-dependent TGFb-2 upregulation, which was necessary for MUC4 induction via an as yet undefined pathway (Choudhury et al., 2000) . Interestingly, IFNg and RA are well known for their ability to evoke a synergistic effect, which generally leads to an enhanced induction of target gene(s) and an exacerbation of the associated biological response(s). The impact of this synergism has been observed in a wide range of malignant tumour cell types, including breast, oral, neuroblastoma, leukemic and renal cancer cells (Ho, 1985; Windbichler et al., 1996; Widschwendter et al., 1997; Guzhova et al., 2001; Yang et al., 2001; Hu et al., 2002) , but has remained largely unexplored in pancreatic tumour cells and, therefore, raises important questions.
In light of these observations, we have conducted the present study to investigate the interactions of IFNg-and RA-induced signalling pathways in the context of MUC4 induction, and to characterize the molecular bases of these interactions. Using the CD18/HPAF-SF cell system, we demonstrate that IFNg and RA synergize potently to induce MUC4 expression. RARa and RARg are upregulated by IFNg-RA combinations, pointing to their potential implication in the synergism. Interestingly, examination of the signalling effectors associated with pathways activated by IFNg or RA indicates that the upregulation of STAT-1 by IFNg is partially inhibited by RA. Likewise, the TGFb-2-dependent pathway, which is normally activated by RA (Choudhury et al., 2000) , is repressed by IFNg, suggesting the involvement of additional mechanism(s). Moreover, results from luciferase reporter gene assays suggest a cooperative activation of the MUC4 promoter by IFNg and RA. Together, these data reflect a reprogramming of signalling pathways through alternative routes during the synergistic interaction of two distinct biological inducers.
Results

Synergistic induction of MUC4 expression by IFNg and RA
We have recently demonstrated that IFNg and RA (Choudhury et al., 2000) are potent inducers of MUC4 in pancreatic tumour cells. In various cell systems, both reagents have been shown to interact synergistically, thereby enhancing the expression of specific sets of genes and the associated biological responses (Ho, 1985; Windbichler et al., 1996; Widschwendter et al., 1997; Guzhova et al., 2001; Hu et al., 2002) . To evaluate the effect of a combined IFNg-RA treatment on MUC4 induction, CD18/HPAF-SF cells were stimulated with different doses of each reagent, which were applied either alone or in combination. Cells were harvested at 48 h poststimulation and subjected to RNA slot blot and Western blot analyses. Our results revealed that cotreatment of cells with IFNg and RA elicited a dramatic upregulation of MUC4 transcript and protein ( Figure 1a and b, respectively). For all of the doses tested, cells concomitantly exposed to IFNg and RA exhibited enhanced MUC4-specific signals that were greater (up to threefold; e.g. IFNg (25 ng/ml)/RA (10 nM); IFNg (50 ng/ml)/ RA (10 nM)) than signals expected from an additive effect of both types of stimuli ( Figure 1a ). These observations indicate that IFNg and RA interact synergistically to induce MUC4 expression in CD18/ HPAF-SF cells.
Involvement of alternative pathway(s) in the synergistic induction of MUC4
We subsequently sought to delineate the molecular mechanism(s) underlying the synergistic interaction of IFNg and RA. Our recent studies have demonstrated that MUC4 induction by IFNg in CD18-HPAF-SF cells critically depends on STAT-1 upregulation . Moreover, various studies have reported the ability of RA to stimulate the production of STAT-1 and other signalling effectors in several malignant cell systems. Increased STAT-1 expression was shown to enhance the responsiveness of RA-treated cells to IFNs (Kolla et al., 1996; Gianni et al., 1997; Chelbi-Alix and Pelicano, 1999; Niitsu et al., 2002) . Given that STAT-1 upregulation is critical to MUC4 induction by IFNg , we investigated the expression profile of this transcription factor in IFNg-and RA-stimulated CD18-HPAF-SF cells. Consistent with our previous observations , Western blot analyses revealed an augmented expression of STAT-1 in cells treated with IFNg ( Figure 2a, lanes 2-4) . In contrast, RA treatment reduced the constitutive expression of STAT-1 (lanes 9 and 13). Furthermore, coadministration of IFNg and RA resulted in a partial, albeit statistically significant, inhibition of STAT-1 induction by IFNg (lanes 6-8, 10-12, and 14-16). Thus, our data point to two possibilities. First, the contribution of STAT-1 upregulation to the synergistic induction of MUC4 by IFNg and RA may not be as critical as it is in cells treated with IFNg alone. Alternatively, the extent to which this transcription factor is upregulated may be sufficient to support its inducing effect during the synergistic interaction.
A similar approach was taken to investigate the role of TGFb-2, a key mediator of RA-induced MUC4 expression (Choudhury et al., 2000) , in IFNg-RA synergism. Essentially, cells subjected to the same treatments as above were examined for the expression of this cytokine. In agreement with our previous findings (Choudhury et al., 2000) , treatment of cells with RA elicited TGFb-2 upregulation in a dose-dependent manner. However, IFNg exerted an inhibitory effect on both the basal and RA-induced expression of TGFb-2 (Figure 2b ). Thus, TGFb-2 may not play a principal role in mediating the synergistic induction of MUC4 as it is observed in cells treated with RA alone (Choudhury et al., 2000) . Taken together, these observations indicate that the signalling pathway(s) involved in the synergistic induction of MUC4 by IFNg and RA may differ from P-labelled cDNA probes specific for MUC4 or GAPDH (internal control). The bar graph represents the intensity of MUC4-specific signal adjusted to GAPDH. Error bars indicate the standard deviation from triplicate values. (b) Samples of total protein from cell lysates were electrophoresed on 2% SDS-agarose gel and blotted onto PVDF membrane. Blots were subsequently processed according to the standard Western blotting protocol using a MUC4-specific monoclonal antibody. Aliquots from all samples were resolved on 10% Laemmli SDS-polyacrylamide gel. Blots were generated and probed with anti-PGK polyclonal antibody (internal control). Shown are representative data from at least three independent experiments Regulation of MUC4 by IFNc and RA M Andrianifahanana et al those normally activated by either reagent, when applied individually.
Role of modulated receptor expression in IFNg-RA synergism
Previous studies have established the role of RA receptors as a basis for the synergistic interaction of IFNg and RA in various cell types. Upregulation of RARb was shown to enhance the responsiveness of cells to treatment with IFNg (Niitsu et al., 2002) . Moreover, our own studies have demonstrated the implication of RARa in RA-induced MUC4 expression (Choudhury et al., 2000) . To evaluate the relevance of RARs to IFNg/RA synergism, we examined the expression profiles of transcripts for RARa, -b, and -g in CD18/ HPAF-SF cells following treatment with various doses of IFNg and RA, either alone or in combination. Total The bar graphs (mean7standard deviation) represent the intensity of STAT-1-specific signals adjusted to PGK. Shown are data from three independent experiments. Analysis with one-way ANOVA indicated a statistically significant difference among the treatment groups (n ¼ 3; Po0.001). Relevant comparisons by t-test that revealed a statistically significant difference (Pp0.05) include lane 1 vs 9, 1 vs 13, 3 vs 7, and 7 vs 11. (b) Total RNA was analysed by RT-PCR using primers specific for TGFb-2 or GAPDH (internal control). PCR products were resolved on 2% agarose gel stained with ethidium bromide. Photographs were taken under UV light. The bar graphs (mean7standard deviation) represent the intensity of TGFb-2-specific signals adjusted to RPL13A. Shown are representative data from at least three independent experiments. Analysis with one-way ANOVA indicated a statistically significant difference among the treatment groups (n ¼ 3; Po0.001). Relevant comparisons by t-test that revealed a statistically significant difference (Pp0.05) include lane 1 vs 2, 1 vs 3, 4 vs 6, 7 vs 8, 7 vs 9, and 8 vs 9. Lane 10 shows the expression of TGFb-2 mRNA in the CD18/HPAF parental cells, grown in serum-containing medium Regulation of MUC4 by IFNc and RA M Andrianifahanana et al
RNAs from cells subjected to the indicated treatments were initially tested by semiquantitative reverse transcription (RT)-PCR at low cycle (linear range). This was to determine whether any of the receptors under study showed any changes in their respective expression patterns that paralleled that of MUC4. The receptors that fit this criterion were further analysed by quantitative RNA slot blotting, and one-way analysis of variance (ANOVA) was performed to reveal any statistical differences among the treatments tested. Our results revealed a dose-dependent upregulation of RARa following treatment with IFNg (Po0.05) or with RA at 100 nM (P ¼ 0.003) (Figure 3a) . Interestingly, RARa expression in cells cotreated with IFNg and RA was further enhanced compared to cells treated with either reagent alone ( Figure 3a ). Likewise, RARg was dosedependently upregulated both by IFNg and RA (Figure 3c ), although the expression of this receptor isoform was further upregulated only in cells subjected to a combined treatment with lower doses of the reagents (i.e., Figure 3c : (IFNg 12.5 ng/ml þ RA 10 nM) vs (IFNg 12.5 ng/ml) or (RA 10 nM)). In contrast, under all concentrations of IFNg and RA tested, RARb expression did not display a pattern consistent with that of MUC4 ( Figure 3b ). Despite the slight upregulation of this transcript by some of the individual treatments (e.g., IFNg 50 ng/ml, RAX10 nM), most of the combined treatments resulted in a reduced expression of the receptor (e.g., Figure 3c ; (IFNg 50 ng/ml) vs (IFNg 50 ng/ml þ RA 100 nM)).
To further explore the role of RARa in the synergistic induction of MUC4, cells were treated with IFNg, RA, or IFNg þ RA, in the presence or absence of the RARaspecific inhibitor, Ro41-5253. Results from Western blot analyses revealed that neither Ro41-5253 nor DMSO (solvent) affected the constitutive expression of MUC4 (Figure 4a ). Moreover, Ro41-5253 dose-dependently inhibited the RA-dependent MUC4 induction (Figure 4c ), which was consistent with our previous observations (Choudhury et al., 2000) . Likewise, the synergistic induction of MUC4 by a combination of IFNg and RA was also inhibited by Ro41-5253 (Figure 4d ), indicating that RARa was required for the IFNg/RA synergism. However, to our surprise, the stimulation of MUC4 by IFNg was also negated by treatment with the RARa-specific inhibitor (Figure 4b ). To determine the mechanistic basis of this inhibitory effect, we examined the expression profile of STAT-1, a transcription factor whose upregulation by IFNg is critical to the induction of MUC4 by this cytokine . Results from Western blot analysis demonstrated that STAT-1 was downregulated by Ro41-5253 in a dose-dependent manner, and that no further upregulation of this transcription factor was observed in response to treatment with IFNg ( Figure 4b , middle row). Thus, these data suggest that RARa is required for both the constitutive expression of STAT-1 and the synergistic induction of MUC4 by IFNg and RA.
We next investigated the expression profiles of both subunits of the IFNg receptor. As evaluated by RNA slot blot analysis, IFNg upregulated the expression of IFNGR-1 mRNA at 50 ng/ml (P ¼ 0.02), while RA did not significantly affect the levels of this receptor (Figure 5a ). Although certain IFNg/RA combinations appeared to potentiate the stimulation of IFNGR-1 mRNA expression by either reagent (e.g., (IFNg 12.5 ng/ ml þ RA 10 nM) vs (IFNg 12.5 ng/ml) or (RA 10 nM)), no statistically significant difference was observed among the effects of these treatments (Figure 5a ). In contrast, the levels of IFNGR-2 mRNA did not exhibit any significant fluctuation in response to the treatments tested, as revealed by one-way ANOVA (Figure 5b) . Moreover, the overall pattern of expression for this receptor subunit was not consistent with MUC4 Figure 3 Dynamics of RA receptor expression. CD18/HPAF-SF cells were exposed to the indicated doses of IFNg and/or RA for 48 h. Cells were harvested and processed for RNA isolation. Total RNA was analysed by RNA slot blot using 32 P-labelled cDNA probes specific for RARa (a), RARg (c), or GAPDH (internal control), or by RT-PCR using primers specific for RARb (b) or RPL13A (internal control). The bar graphs (mean7standard deviation) represent the intensity of target gene-specific signals adjusted to the respective internal controls. Shown are data from three independent experiments. Analysis with one-way ANOVA indicated a statistically significant difference among the treatment groups for all experiments (n ¼ 3; Po0.001). Relevant comparisons by t-test that revealed a statistically significant difference (Pp0. (Figure 1 ). Together, these observations suggest that upregulation of RARa and RARg may potentiate the synergistic induction of MUC4 by IFNg and RA. The exact mechanisms underlying the contribution of these receptor subtypes are currently being investigated in our laboratory.
Reprogramming of signalling pathway(s) during the synergistic induction of MUC4
Thus far, we have demonstrated that the synergistic induction of MUC4 by IFNg and RA is a complex process that cannot be explained by a simple unilateral or reciprocal enhancement of the signalling pathways triggered by either reagent alone (Figure 2) . We have previously reported that IFNg was capable of inducing a modest transactivation of cloned MUC4 promoter fragments that contained putative STAT binding sites termed IFNg-activated sequence (GAS) (Perrais et al., 2001) . A subsequent motif search performed on different MUC4 promoter fragments revealed the presence of several putative transcription factor binding sites, including a total of four potential STAT, four RAR, and one RXR cis-element (Figure 6 ). These observations prompted us to examine the effect of IFNg and RA stimulation at the MUC4 promoter level. Luciferase reporter gene assays were implemented to evaluate the impact of IFNg-RA synergism on MUC4 promoter activity. A panel of MUC4 promoter deletion constructs ( Figure 6 ) was transfected into CD18/HPAF-SF cells and evaluated for their ability to drive the expression of a promoterless luciferase gene, following the treatment of cells with different concentrations of IFNg and/or RA. Results from luciferase assays indicated that the deletion constructs under study (except for fragment P-1809), most of which harboured binding elements for STAT and/or RAR/RXR (retinoic acid response P-labelled cDNA probes specific for IFNGR-1 (a) or GAPDH (internal control), or by RT-PCR using primers specific for IFNGR-2 (b) or RPL13A (internal control). The bar graphs (mean7standard deviation) represent the intensity of target gene-specific signals adjusted to the respective internal controls. Shown are data from three independent experiments. Analysis with one-way ANOVA indicated a statistically significant difference among the treatment groups for IFNGR-1 (n ¼ 3; Po0.001) but not for IFNGR-2
Regulation of MUC4 by IFNc and RA M Andrianifahanana et al element (RARE)), were responsive to stimulation by IFNg or RA in a dose-dependent manner ( Figure 6 ). Of particular interest was the deletion construct P-2150, which evidenced a cooperative effect of IFNg and RA on promoter activity. In cells transfected with this construct, transcriptional activity was induced 1.7-and 1.2-fold in the presence of IFNg (50 ng/ml) and RA (100 nM), respectively, and further enhanced (2.5-fold) in the simultaneous presence of both reagents ( Figure 6 and Table 1 ). Interestingly, this fragment carried a larger number of potential STAT binding sites as compared with other fragments and highlighted the presence of an RXR cis-element in addition to the RAR binding sites (Figure 6 ). A similar pattern of induction was also observed with the P-1959 and P-1641 fragments, which, in turn, were located within the TATAcontaining region ( Figure 6 and Table 1 ). An enhanced transcriptional activity (P-1959 (2.4-fold); P-1641 (3.2-fold)) was also recorded in cells cotreated with IFNg or RA, as compared with those individually stimulated with IFNg at 50 ng/ml (P-1959 (1.7-fold); P-1641 (2.3-fold)) or RA at 100 nM (P-1959 (1.1-fold); P-1641 (1.3-fold)) (Table 1) . Importantly, these observations are consistent with findings from studies that identified several active transcription start sites both within TATA-containing and TATA-less regions of the MUC4 promoter (Perrais et al., 2001) . Overall, our data indicate that multiple regions within the MUC4
promoter constitute potential zones of convergence for transcription factors activated by IFNg and RA and may partly account for the synergistic effect on MUC4 gene induction. In consideration of the respective pathways activated by IFNg and RA in the context of MUC4 regulation, these findings suggest a rerouting of signalling via alternative pathway(s) during the synergistic interaction of these MUC4 inducers.
Temporal aspect of IFNg/RA-triggered MUC4 induction
In a parallel study, we have consistently observed the expression of IFNg transcript in pancreatic tumours, which contrasted with a lack of detection in normal pancreatic tissues (Andrianifahanana et al., 2005) . . Analysis with one-way ANOVA indicated a statistically significant difference (n ¼ 3; Po0.001) among the treatment groups for P-1641, P-1959, and P-2150, but not for P-1809 or pGL3 basic. Pairwise comparisons by t-test revealed a statistically significant difference (Pp0.05) among all treatments within each group except for the following: P-1959: (untreated) vs (RA (100 nM)); and P-1641: (IFNg (50 ng/ml)) vs (IFNg (50 ng/ml) þ RA (100 nM)). Comparisons did not include (IFNg (50 ng/ml)) vs (RA (100 nM)) Figure 7 , lanes 3 and 6) but not RA (lanes 10 and 13) were more potent at inducing MUC4 than the corresponding individual treatments (IFNg: lanes 2 and 5; RA: lanes 8 and 10, respectively). Moreover, when cells were primed with IFNg, the extent of MUC4 induction in cells that had received reciprocal treatments (IFNg-RA: lanes 4 and 7) appeared to exceed those in cells subjected to duplicated treatments (lanes 3 and 6). Most interestingly, the levels of MUC4 in these reciprocally treated cells were comparable to those detected in cells exposed to the IFNg-RA control treatment (lane 16). Taken together, these observations indicate that the continuous presence of IFNg or RA is not required for a synergistic induction of MUC4, and that priming with either reagent for a period of time as short as 8 h is sufficient to potentiate each other's effect. In consideration of the functional properties of MUC4 (see Discussion), these findings may have important biological implications with respect to the development of pancreatic tumours in vivo.
Discussion
In this study, we have elucidated important aspects of the molecular events associated with the synergistic induction of the MUC4 gene by IFNg and RA in pancreatic tumour cells. We demonstrate that the mechanism(s) underlying the concerted regulation of MUC4 by these biological modifiers diverge to some extent from those operated by cells subjected to stimulation with each reagent alone. Moreover, the profiles of MUC4 promoter activity support a cooperative activation by both reagents at the transcriptional level. Together, these observations indicate a rerouting of signalling during the synergistic interaction of IFNg and RA, and reflect an extensive flexibility of the signalling pathways activated by each or both biological stimuli within a single cell system. Our recent studies have shown that upregulation of MUC4 by IFNg in CD18/HPAF-SF cells depends on elevated expression of STAT-1 transcription factor , and that its stimulation by RA implicates TGFb-2 as a critical mediator (Choudhury et al., 2000) . Thus, one may predict that a synergistic induction of this mucin gene by IFNg and RA would occur via amplification of the molecular signals instigated by each type of stimulus. Alternatively, modulation of receptor expression may impart enhanced cell responsiveness to either ligand, thereby leading to a synergistic effect, as observed with other systems (Niitsu et al., 2002) . However, as demonstrated in this study, treatment of cells with RA repressed the constitutive expression of STAT-1 and partially inhibited its induction by IFNg (Figure 2a) . Furthermore, expression of the RA signalling mediator, TGFb-2, was repressed by IFNg (Figure 2b ). In contrast, RARa (Figure 3a) and RARg ( Figure 3c ) were induced by RA and/or IFNg, and these receptor isoforms were further upregulated by certain IFNg-RA combinations. Therefore, one of the most plausible explanations to the synergistic induction of MUC4 is a rerouting of the signalling pathway(s) engaged in the simultaneous presence of IFNg and RA, whereby upregulation of RARa and/or RARg may play a role in IFNg-RA synergism. Indeed, analysis of the transcriptional activity of various MUC4 promoter deletion constructs evidenced a cooperative effect of IFNg and RA at the promoter level (Figure 6 ), suggesting a potential interaction of the transcription factors, STAT-1 and RAR/RXR, with the MUC4 promoter. These arguments are corroborated by the presence of several potential STAT and RAR/RXR binding sites within the MUC4 promoter region (Figure 6 ). In that line of reasoning, these observations indicate that cotreatment of cells with IFNg and RA may activate alternative pathway(s) that bypass those engaged by each reagent alone, specifically the TGFb pathway in the present case. At this point, the exact mechanism(s) involved is still unclear and is the subject of our ongoing investigations. One of the hypotheses being tested is that, in the presence of RA alone, the native chromosomal context of the MUC4 promoter may prohibit the access of RAR/RXR to their cognate cis-elements, which would favour the prevalence of TGFb signalling as the major pathway for RA-driven MUC4 gene regulation. Induction of STAT-1 following IFNg treatment may alleviate the constraints imposed by the chromosomal structures, thereby increasing the accessibility of RAR/RXR binding sites and allowing for the synergistic induction to take place. Under these circumstances, the repressive effect of IFNg on RA-induced TGFb expression would have little or no impact on MUC4 induction. Here, inhibition of TGFb-2 expression may have resulted from upregulation of SMAD7 (our unpublished data), an inhibitory SMAD that functions as a negative regulator of the TGFb signalling pathway (Ulloa et al., 1999) . In this respect, a recent study has described the interference of IFNg-induced SMAD7 with TGFb-dependent regulation of the sialomucin complex (SMC), the MUC4 homologue in rat (Soto et al., 2003) . Overall, a simplified model is proposed to summarize our findings regarding MUC4 regulation in pancreatic tumour cells (Figure 8 ). This model depicts the signalling pathways implicated in MUC4 upregulation by IFNg and RA, and highlights the complex interplay between pathways activated during the synergism. On the other hand, additional signalling pathway(s) may likewise be involved in this synergistic interaction. As illustrated by the case of the promoter fragment, P-1959, a dose-dependent induction of luciferase gene expression had taken place although no STAT binding site was identified in this fragment (Figure 6 ). In this regard, we have recently shown that the STAT-1-mediated elicitation of MUC4 expression is dependent on JAK(s) , a tyrosine kinase that serves as a platform for the activation of several distinct IFNg-triggered pathways (Ramana et al., 2002) . Interestingly, the upregulation of IFNGR-1 mRNA by IFNg (Figure 5a ) may be of particular relevance to this point, although the exact role of this receptor subunit in this context still remains unclear. Moreover, the influence of secondary responses in IFNg-RA synergism cannot be ruled out. Intermediate effectors whose expression is induced by factors activated by the primary stimuli (IFNg or RA) may come into play during the synergistic interaction.
The importance of these findings lies with their implications in the pathobiology of pancreatic cancer, particularly with respect to two sets of observations. On (Choudhury et al., 2000) , although the regulatory process may also involve a direct activation of MUC4 by an RARa-containing complex (dotted green arrow). Right panel: synergistic regulation of MUC4 by IFNg and RA. Induction of MUC4 involves a reprogramming of signalling pathway(s). While STAT-1 induction by IFNg is partially repressed by RA (red dotted line), the upregulation of TGFb-2 by RA is inhibited by IFNg. The dotted blue line depicts a presumptive pathway (Ulloa et al., 1999) (our unpublished data) that may account for the inhibition of TGFb-2 expression, which leads to the attenuation of the TGFb-2-dependent pathway (dotted green arrow) the one hand, IFNg and RA are naturally occurring biological agents with proven cell growth inhibitory and/or differentiating properties (Ho, 1985; Windbichler et al., 1996; Widschwendter et al., 1997; Chelbi-Alix and Pelicano, 1999; Guzhova et al., 2001; Yang et al., 2001; Hu et al., 2002) . Moreover, our recent studies have indicated a differential expression of IFNg in pancreatic tumours, as opposed to the lack of detection in the normal pancreas (Andrianifahanana et al., 2005) . On the other hand, both compounds are presently shown to promote the synergistic induction of MUC4, a tumourassociated molecule that is known to promote tumour cell growth and/or metastasis in several experimental systems (Komatsu et al., 2000; Singh et al., 2004) . These observations raise important questions regarding the ultimate behaviour of pancreatic tumour cells in response to IFNg and RA in vivo. A legitimate avenue to addressing this situation is to draw on information about the functional properties of MUC4. Although the exact biological functions of human MUC4 have only begun to be understood (Singh et al., 2004) , the high degree of structural similarity between this mucin and its orthologue, rat Muc4/SMC, strongly suggests similar functions (Sheng et al., 1992; Wu et al., 1994; Moniaux et al., 1999) . Rat Muc4/SMC has been implicated in the promotion of tumour cell metastasis in vivo (Komatsu et al., 2000) . Its overexpression on the cell surface enables human A375 melanoma cells to escape immune surveillance, presumably via masking of key recognition molecules that are necessary for tumour cell targeting by immune effector cells (Komatsu et al., 1999) . Likewise, ectopic expression of MUC1, another member of the transmembrane mucin family, has been shown to potentiate the immune evasion capabilities of A375 cells. Overexpression of this mucin provides augmented protection of the tumour cells against killing by activated cytotoxic immune effector cells (van de Wielvan Kemenade et al., 1993) . MUC1 has also been shown to inhibit cell-cell interaction mediated by the cell adhesion molecule, E-cadherin (Wesseling et al., 1996; Kondo et al., 1998) . In view of the structural analogy between MUC4 and its rat counterpart (Sheng et al., 1992; Wu et al., 1994; Moniaux et al., 1999) , the functional roles of MUC1 (van de Wiel-van Kemenade et al., 1993; Wesseling et al., 1996; Kondo et al., 1998) , and the predicted large size and extended structure of MUC4 (Moniaux et al., 1999) , the aberrant expression of MUC4 on the surface of pancreatic tumour cells may potentially provide protection against the host's activated immune system while conferring antiadhesive/ metastatic properties upon the cells. These statements are further supported by information regarding the structural features of MUC4, whose ectodomain is predicted to extend B2 mm (vs 200-500 nm for MUC1; Wesseling et al., 1996) above the cell surface (Moniaux et al., 1999) . Furthermore, our observations from recent functional studies suggest a role of MUC4 in promoting the growth and metastasis of pancreatic tumour cells in vivo (Singh et al., 2004) . On the other hand, the present results from priming experiments indicated that induction of MUC4 did not require the continuous presence of either IFNg or RA (Figure 7) . Although IFNg has been previously shown to inhibit pancreatic tumour cell growth in vitro (Matsubara et al., 1991; Detjen et al., 2001) , details about the temporal aspect of this process have remained unexplored. In addition, we have observed that RA does not affect the proliferation of CD18/HPAF-SF cells while promoting the growth of the parental cell line, CD18/HPAF (AP Singh and SK Batra, unpublished observations). Evaluation of the requirements (e.g., time and duration of exposure) that define the respective physiological effects of IFNg and RA would therefore be of particular interest in order to identify their impact on pancreatic tumour cell behaviour. Overall, the current data on MUC4 gene regulation provide a potential mechanism underlying its aberrant expression in pancreatic tumour cells in vivo, and illustrate how it may interfere with the proper functioning of the host's defence system, thereby contributing to the pathogenesis of pancreatic cancer.
In conclusion, we have demonstrated that IFNg and RA can synergize potently to effect MUC4 induction in pancreatic tumour cells. An improved understanding of the mechanism(s) underlying the regulation of this mucin gene may provide useful insights into the molecular events underlying the pathogenesis of pancreatic cancer, and may significantly impact the development of therapeutic strategies using MUC4 as a novel target.
Materials and methods
Cell lines and reagents
The pancreatic tumour cell line, CD18/HPAF, and its derivative, CD18/HPAF-SF, were used in this study. CD18/ HPAF cells were maintained in a 1 : 1 mixture of Dulbecco's modified Eagle's medium (DMEM) : Ham's F-12 medium supplemented with 10% fetal bovine serum (FBS). CD18/ HPAF-SF cells were grown in the same culture medium without serum. All reagents for cell culture were purchased from Invitrogen. In stimulation experiments, CD18/HPAF-SF cells were seeded in six-well plates or in 10-cm Petri plates and allowed to reach B70% confluency prior to treatment. Cells were treated with the indicated doses of IFNg (Peprotech) and/or all-trans retinoic acid (RA) (Sigma), which was used either individually or in combination. For priming experiments, cells were treated with the indicated concentrations of IFNg or RA for 8 or 16 h, rinsed twice in culture medium, and subsequently restimulated with either reagent for 48 h according to the described experimental layout. Cells were harvested and processed for RNA or protein extraction as described below.
In inhibition experiments, cells were preincubated with the RARa-specific inhibitor, Ro41-5253 (a gift from Hoffman/ LaRoche), for 30 min prior to the indicated treatments.
RNA isolation and reverse transcription-PCR analysis
Total RNA was isolated from cells using the RNeasy s Mini Kit (Qiagen). Reverse transcription was performed on 2 mg of RNA per sample using the SuperScripttII RNase À Reverse Transcriptase system (Invitrogen). The cDNA samples were subjected to PCR amplification using the parameters provided in Table 2 (Choudhury et al., 2000; Andrianifahanana et al., 2001; Jesnowski et al., 2002) . RPL13A was used as an internal control. PCR products were electrophoretically resolved on 2% agarose gels stained with ethidium bromide. Photographs were taken under UV light, and densitometric analyses of DNA bands were carried out using the Gel Expert software system (Nucleotech).
RNA slot blot analysis
Total RNA (10 mg per sample) was denatured in a buffer containing formamide/formaldehyde and blotted onto nylon membranes by vacuum suction, using a 48-well slot filtration manifold system (Invitrogen). All samples were analysed in triplicate. Membranes were prehybridized at 421C for 12 h in 6 Â saline/sodium phosphate/ethylene diamine tetra acetate, 5 Â Denhardt's reagent, 0.5% sodium dodecyl sulphate, 50% formamide, and 100 mg/ml of sheared salmon sperm DNA. Hybridization was conducted under the same conditions in the presence of 32 P-labelled cDNA probes specific for the indicated target genes. Membranes were exposed to a PhosphorImager screen, and subsequent analyses were carried out using the ImageQuaNTt software (Molecular Dynamics). Membranes were further stripped and rehybridized with a 32 P-labelled, glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific cDNA probe (internal control).
Western blot analysis
Cells were lysed in modified RIPA buffer (50 mM Tris-HCl, pH 7.4; 0.25% Na-deoxycholate; 150 mM NaCl; 1% NP-40; 1 mM EDTA), supplemented with 1 mg/ml aprotinin, 1 mg/ml leupeptin, 5 mM NaF, 5 mM Na 3 VO 4 , and 1 mM phenylmethylsulphonyl fluoride (PMSF). Proteins were extracted on ice for 30 min and further cleared by centrifugation at 16 000 g for 10 min. Supernatants (protein extracts) were collected and stored at À801C until further use.
Total protein was electrophoretically fractionated on 10% Laemmli SDS-polyacrylamide gels and electroblotted onto PVDF membranes. Blotted membranes were blocked in 5% blotto (nonfat dry milk in phosphate-buffered saline) and subsequently exposed to primary antibodies specific for STAT-1 p91 (Santa Cruz Biotechnology) diluted in 1% blotto. Following incubation in the appropriate secondary antibody, membranes were treated with ECL reagents (Amersham Biosciences) and exposed to autoradiographic films. Membranes were stripped and reprobed with antibodies specific for phosphoglycerate kinase (PGK) (internal control; kindly provided by Dr JK Vishwanatha, UNMC, Omaha, NE, USA).
Due to the predicted large size of the mature MUC4 glycoprotein (in the megadalton range), Western blot analysis of this mucin was carried out on 2% SDS-agarose gels. Subsequent experimental procedures were essentially as stated above with the exception that protein transfer was achieved by capillary blotting. The primary antibody consisted of an MUC4-specific mouse monoclonal antibody produced in our laboratory (clone 8G7) (Swartz et al., 2002; Moniaux et al., 2004) .
MUC4 promoter deletion constructs, transfection, and luciferase reporter gene assay
A total of four promoter deletion constructs carrying DNA fragments covering various regions of the MUC4 gene 5 0 -flanking sequence were used in this study ( Figure 6 ; Perrais et al., 2001) . DNA inserts consisted of two fragments located within a TATA-less region of MUC4 5 0 -flanking sequence (P-1809 (À219/À1) and P-2150 (À1187/À1)) and two fragments within a TATA-containing region (P-1959 (À2781/À2572) and P-1641 (À3135/À2572)). All inserts were subcloned into the promoterless pGL3 Basic vector (Promega) in the sense orientation. Constructs (2 mg) were cotransfected with the pSV-bGal vector (0.2 mg) (Promega) into CD18/HPAF-SF cells 24 h after seeding using the FuGENE 6 transfection reagent (Roche). Cells were treated with the indicated concentrations of IFNg and/or RA at 24 h post-transfection and allowed to incubate in the presence or absence of the reagents for another 40 h prior to harvesting. Cell lysates were prepared in triplicate, and luciferase activity was assessed and corrected with b-galactosidase activity for transfection efficiency.
Statistical analyses
For each experiment, one-way ANOVA was used to determine whether there was a statistically significant difference among the groups. Further pairwise comparisons to examine differences between the treatments groups were performed using t-tests. 
